Skip to main content
. 2022 Nov 24;55:101746. doi: 10.1016/j.eclinm.2022.101746

Fig. 2.

Fig. 2

Overall survival comparison between neoadjuvant therapy vs no neoadjuvant therapy in the propensity score matched group (n = 700), missing data on censoring variable or date of death (n = 8). Hazard ratio 1.08 (95% CI: 0.88–1.32), p-value 0.46. Median OS 34.7 months in the neoadjuvant group (95% CI: 31.2–38.8) vs 37.0 months in the no neoadjuvant group (95% CI: 32.6–42.7), log rank p-value 0.46.